BioSpace News Archive

Motus GI Holdings, Inc. announced that the Company received written notification from the Listing Qualification Department of The NASDAQ Capital Market granting the Company’s request for a 180-day extension to regain compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550.

Achieve Life Sciences, Inc. today announced it will report its fourth quarter and year-end 2021 financial results and provide an update on the cytisinicline development program on Thursday, March 10, 2022, at 4:30 PM EST.

89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, announced the appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors.

Vivos Therapeutics, Inc. announced that its Vivos Medical Advisory Board has been selected to present a retrospective review of sleep therapy data from patients treated with the Vivos Method at this year’s World Sleep Congress on March 11–16, 2022.

Pasithea Therapeutics Corp. announced that its wholly owned subsidiary, Pasithea Clinics, has expanded its treatment offerings and is planning to open three new clinics in London to treat patients suffering from mental health issues.

Reports full year 2021 revenue of $85.4 million, above pre-announced preliminary range Reiterates 2022 revenue outlook

Genus plc is pleased to announce that PIC has entered into definitive agreements with Olymel LP, a leader in the Canadian agrifood industry, for provision of genetic products and services in connection with the Olymel’s AlphaGene porcine genetic improvement program.

HAVN Life Sciences Inc. is pleased to announce it has successfully secured a purchase order for naturally derived psilocybin from their Canadian supply partner, Revive Therapeutics Ltd.

Ardelyx, Inc. announced that it has entered into a debt financing agreement with investment affiliates managed by SLR Capital Partners.

Contraline, Inc. announced that its ADAM™ System, the world’s first investigational hydrogel implant designed to provide non-hormonal, long-lasting and non-permanent contraception for men, was awarded “Best Innovation,” at the 2022 Women’s Health Innovation Series: Reproductive Health Innovation Summit, held in Boston on February 15-16, 2022.